New HER2-directed therapies for breast cancer

Commentary re: C. I. Spiridon et al., Targeting multiple HER-2 epitopes with monoclonal antibodies results in improved antigrowth activity. Clin. Cancer Res., 8: 1720-1730, 2002

Research output: Contribution to journalArticle

8 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)1699-1701
Number of pages3
JournalClinical Cancer Research
Volume8
Issue number6
StatePublished - 2002

Fingerprint

ErbB-2 Receptor
Antibody-Dependent Cell Cytotoxicity
Surface Antigens
Epitopes
Monoclonal Antibodies
Breast Neoplasms
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{978f86e2ab5245119a6b8055c29e74af,
title = "New HER2-directed therapies for breast cancer: Commentary re: C. I. Spiridon et al., Targeting multiple HER-2 epitopes with monoclonal antibodies results in improved antigrowth activity. Clin. Cancer Res., 8: 1720-1730, 2002",
author = "Frankel, {Arthur E.}",
year = "2002",
language = "English (US)",
volume = "8",
pages = "1699--1701",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - New HER2-directed therapies for breast cancer

T2 - Commentary re: C. I. Spiridon et al., Targeting multiple HER-2 epitopes with monoclonal antibodies results in improved antigrowth activity. Clin. Cancer Res., 8: 1720-1730, 2002

AU - Frankel, Arthur E.

PY - 2002

Y1 - 2002

UR - http://www.scopus.com/inward/record.url?scp=0036284501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036284501&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 1699

EP - 1701

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -